Altkirch, France

Francois Gessier

USPTO Granted Patents = 5 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Illfurth, FR (2012)
  • Altkirch, FR (2013 - 2021)

Company Filing History:


Years Active: 2012-2021

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Francois Gessier

Introduction

Francois Gessier is a notable inventor based in Altkirch, France, recognized for his significant contributions to the field of pharmaceuticals. With a total of five patents to his name, Gessier has made strides in developing new compounds that have the potential to address various medical conditions.

Latest Patents

One of Gessier's latest patents involves amino pyrimidine derivatives. This invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts that interact with Bruton's tyrosine kinase (Btk). The novel amino pyrimidines may be effective in treating autoimmune disorders, inflammatory diseases, allergic diseases, and airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, these compounds may play a role in transplant rejection and cancers, including those of hematopoietic origin or solid tumors.

Career Highlights

Throughout his career, Gessier has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Irm LLC. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Francois Gessier has collaborated with several professionals in his field, including Daniela Angst and Anna Vulpetti. These collaborations have likely enhanced his research and development efforts.

Conclusion

Francois Gessier's work in developing amino pyrimidine derivatives showcases his commitment to advancing medical science. His contributions have the potential to impact the treatment of various diseases significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…